Want to see MESO full AI Analyst Report?
MESO Stock Chart & Stats
$15.31
-$0.67(-4.38%)
At close: 4:00 PM EDT
$15.31
-$0.67(-4.38%)
Day’s Range― - ―
52-Week Range$12.66 - $21.50
Previous CloseN/A
Volume88.14K
Average Volume (3M)252.97K
Market Cap
$2.21B
Enterprise Value$2.34K
Total Cash (Recent Filing)$129.57M
Total Debt (Recent Filing)$135.14M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Sep 02, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding129,874,820
10 Day Avg. Volume346,225
30 Day Avg. Volume252,966
Financial Highlights & Ratios
PEG Ratio2.45
Price to Book (P/B)2.20
Price to Sales (P/S)76.48
P/FCF Ratio-25.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$200.01M
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Commercial Cash GenerationRyoncil's 93% gross margin on $49M H1 sales indicates the product is highly cash generative per unit. Durable margin economics support reinvestment in trials and commercialization, reduce near-term dilution needs and improve the company's ability to fund scaling and manufacturing without relying solely on equity financing.
Broad Payer Coverage And Reimbursement CodingBroad payer coverage across >280M lives, a dedicated J-code and 49 onboarded treatment centers materially lower reimbursement friction. These structural access elements create durable barriers to entry, promote predictable cash collections and support sustained uptake across hospital networks and specialty pharmacies.
Cash Balance And Financing FlexibilityA $130M cash balance plus a $125M non-dilutive facility (with $50M undrawn) gives Mesoblast runway to scale commercial operations and advance near-term filings. This financing flexibility reduces immediate refinancing risk, enables capital deployment into manufacturing and trials, and supports execution over the next several quarters.
Bears Say
Persistent Losses And Operating Cash BurnDespite product revenue, Mesoblast reported a $40.2M H1 net loss and used about $30.3M of operating cash. Continued negative operating cash flow requires ongoing financing or rapid scaling of high-margin sales to reach break-even, exposing the company to execution and funding risk until multiple revenue streams mature.
R&D Spending Surge Pressures ResourcesR&D jumped to $46.2M in H1 as programs and BLA preparations accelerate. While investment supports long-term pipeline value, the sharp increase pressures cash flow and magnifies the need for successful late-stage outcomes; failed or delayed trials would worsen funding needs and slow pathway to diversified revenue.
Revenue Concentration And Multi-year Pipeline TimingRyoncil represented ~95.5% of revenue, leaving Mesoblast reliant on a single newly launched product. Major value drivers—additional label expansions and Phase III/BLA readouts—extend into 2027, so near-term financial performance and valuation hinge on sustained Ryoncil uptake and successful completion of later-stage regulatory milestones.
Mesoblast News
MESO FAQ
What was Mesoblast’s price range in the past 12 months?
Mesoblast lowest stock price was $12.66 and its highest was $21.50 in the past 12 months.
What is Mesoblast’s market cap?
Mesoblast’s market cap is $2.21B.
When is Mesoblast’s upcoming earnings report date?
Mesoblast’s upcoming earnings report date is Sep 02, 2026 which is in 20 days.
How were Mesoblast’s earnings last quarter?
Mesoblast released its earnings results on Feb 25, 2026. The company reported -$0.311 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.241.
Is Mesoblast overvalued?
According to Wall Street analysts Mesoblast’s price is currently Overvalued.
Does Mesoblast pay dividends?
Mesoblast does not currently pay dividends.
What is Mesoblast’s EPS estimate?
Mesoblast’s EPS estimate is -0.07.
How many shares outstanding does Mesoblast have?
Mesoblast has 129,874,820 shares outstanding.
What happened to Mesoblast’s price movement after its last earnings report?
Mesoblast reported an EPS of -$0.311 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went up 0.059%.
Which hedge fund is a major shareholder of Mesoblast?
Currently, no hedge funds are holding shares in MESO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MESO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Adaptive Biotechnologies
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
26.11% Insiders
<0.01% Mutual Funds
0.20% Other Institutional Investors
73.21% Public Companies and
Individual Investors